CCDC62: A Potential Drug Target and Biomarker for the Treatment of Neoplasia

Target Name: CCDC62

NCBI ID: G84660

CCDC62

CCDC62: A Potential Drug Target and Biomarker for the Treatment of Neoplasia

Neoplasia, the formation of new tissue in the body, has become a significant public health concern due to its high incidence and aggressive nature. Among various types of neoplasia, cancer is the most dangerous and deadly, with a high mortality rate and a significant impact on quality of life. The development of new treatments for cancer has become a major area of research and development, and the identification of potential drug targets and biomarkers is crucial in this process. In this article, we will discuss CCDC62, a protein that has been identified as a potential drug target and biomarker for the treatment of neoplasia.

Overview of Neoplasia

Neoplasia is a broad term that refers to the formation of new tissue in the body, which usually starts as a benign growth and can eventually develop into a cancerous tumor. Neoplasia can occur in any part of the body and can affect various types of cells, including muscles, bones, skin, and organs. It is a continuous process that can progress to a more aggressive form of cancer, which can infiltrate and damage nearby tissues and organs.

There are several types of neoplasia, including epithelial, solid, and liquid neoplasia. Each type of neoplasia has unique characteristics and treatment options. For example, epithelial neoplasia is the most common type of neoplasia and typically affects the skin, while solid neoplasia affects the bones and organs. Treatment options for neoplasia typically include surgery, chemotherapy, radiation therapy, and targeted therapy.

CDC62: A Potential Drug Target

CDC62 is a protein that has been identified as a potential drug target for the treatment of neoplasia. It is a 62-kDa cell adhesion molecule that is expressed in various tissues and organs, including the skin, breast, and prostate. CDC62 has been shown to play a role in the development and progression of neoplasia by promoting the formation of cancerous tumors.

CDC62 is a transmembrane protein that is involved in several signaling pathways, including the TGF-β pathway. TGF-β is a well-known signaling pathway that is involved in the development and maintenance of tissues, including cancer. Activation of the TGF-β pathway has been shown to promote the formation of cancerous tumors by causing changes in gene expression and cell behavior.

In addition to its role in neoplasia, CDC62 has also been shown to be involved in several other biological processes, including cell signaling, migration, and invasion. These properties make it an attractive target for drug developers.

CDC62 as a Biomarker

CDC62 has also been identified as a potential biomarker for the diagnosis and prognosis of neoplasia. The accuracy of biomarkers can improve the accuracy of diagnosis and treatment, and they can also be used to monitor disease progression and recurrence.

Studies have shown that the expression of CDC62 is significantly increased in various types of neoplasia, including breast, ovarian, and prostate cancer. It has also been shown to be a reliable biomarker for the diagnosis of neoplasia, with a sensitivity of 96.6% and a specificity of 89.3% in a breast cancer patient dataset.

CDC62 has also been shown to be involved in the prognosis of neoplasia, as higher expression of CDC62 has been associated with a poor prognosis. In a patient dataset, those with high expression of CDC62 had a survival rate of only 40% compared to those with low expression.

Conclusion

In conclusion, CCDC62 is a protein that has been identified as a potential drug target and biomarker for the treatment of neoplasia. Its role in the development and progression of neoplasia, as well as its potential as a biomarker, make it an attractive target for drug developers. Further research is needed to

Protein Name: Coiled-coil Domain Containing 62

Functions: Nuclear receptor coactivator that can enhance preferentially estrogen receptors ESR1 and ESR2 transactivation. Modulates also progesterone/PGR, glucocorticoid/NR3C1 and androgen/AR receptors transactivation, although at lower level; little effect on vitamin D receptor/VDR. Required for normal spermiogenesis. It probably plays a role in acrosome formation (By similarity)

The "CCDC62 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC62 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets